iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

ARTIFICIAL INTELLIGENCE IN THE FIELD OF PHARMACOGENOMICS

Morjina Solaiman,
Sabiha Jannath Tisha,
Mohammed Dawood

ABSTRACT
Artificial Intelligence (AI) has brought about a significant shift in pharmacogenomics, enabling the development of personalized therapeutic models tailored to a patient's genetic makeup. Machine and deep learning algorithms of Artificial Intelligence could, therefore, analyze multiple aspects of genetics information that would accurately forecast patient responses to certain medications and drug prescriptions. The synergy also contributes to increased drug efficacy, reduced adverse drug effects, and enhanced efficiency in drug development. However, this is not yet the case, as there are some limitations to AI in pharmacogenomics, including data privacy concerns, ethical issues, and the need for adequate validation of the framework before it can be implemented in practice.

Keywords:
Artificial Intelligence (AI), Pharmacogenomics, Personalized therapeutic models, Genetic makeup, Machine learning, Deep learning algorithms.

INTRODUCTION

Pharmacogenomics postulates are a part of individualized medicine and involve research on how patients' genetic differences influence the effects of drugs. Some classical approaches to pharmacogenomics have been previously employed, and although practical, they face challenges due to the large amount of genomic information. AI has introduced sophisticated approaches to analyze vast volumes of genomic data, enabling the accurate prediction of personal reactions to medication and, more importantly, informing optimal treatment plans. Machine learning and deep learning are branches of AI that have demonstrated the potential to provide accurate predictions in genomic data related to drug effectiveness and potential side effects. By applying AI in pharmacogenomics treatment plans, healthcare workers will be able to develop credible treatment and patient care plans, which will help reduce cases of drug side effects. At the same time, the use of AI in this context also raises several concerns about privacy, ethics, and the assurance of AI models before they are applied in clinical practice. This article highlights the current and potential state of integration between pharmacogenomics and artificial intelligence, as well as future applications of AI in pharmacogenomics and the obstacles that must be overcome to optimize this integration.

THE ROLE OF AI IN PHARMACOGENOMICS

AI is transforming pharmacogenomics by improving the analysis of complex genomic data. Machine learning and deep learning models identify patterns within vast datasets, enabling more accurate predictions of drug responses (Marques et al., 2024). These models integrate multi-omics data, uncovering relationships between genetic variations and drug efficacy (Abdelhalim et al., 2022).

Advanced algorithms efficiently process large-scale genomic datasets. Convolutional neural networks and recurrent neural networks analyze high-dimensional data to identify biomarkers that influence drug metabolism (Jyothi, 2023). Clustering techniques help classify patients into genetic subgroups, leading to more precise therapeutic recommendations (Lin, Lin, & Lane, 2020).

Predicting drug responses based on genetic variations is a breakthrough. AI models trained on clinical and genomic data assess how individuals metabolize drugs, reducing adverse effects and improving efficacy (Weinshilboum & Wang, 2017). Genetic polymorphisms in drug-metabolizing enzymes play a crucial role in personalized treatment strategies (Taherdoost & Ghofrani, 2024).

AI enhances drug optimization and development by identifying genetic markers linked to efficacy and resistance. Deep learning models analyze clinical trial data to determine the best drug formulations (Boniolo et al., 2021). This accelerates the discovery of precision drugs, particularly in fields like oncology and neurology (Das et al., 2024). AI-driven pharma covigilance systems predict adverse drug reactions using electronic health records and

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

genomic databases (Silva et al., 2024). Natural language processing extracts key information from clinical reports, preventing harmful drug interactions (Navarro, 2023).

Personalized treatment plans benefit from AI-assisted decision-making. Decision-support systems integrate pharmacogenomic data with clinical history, lifestyle factors, and real-time monitoring (Chen et al., 2025). These dynamic treatment strategies continuously adapt based on patient responses and genetic insights (Dhieb & Bastaki, 2025).

AI-driven pharma cogenomic interventions are already improving clinical outcomes. In oncology, AI models match cancer patients with targeted therapies based on tumor genetics (Primorac et al., 2020). In psychiatry, AI-driven analysis facilitates more informed antidepressant selection, thereby reducing the need for trial-and-error prescribing (Pardiñas, Owen, & Walters, 2021).

AI's role in pharmacogenomics is reshaping precision medicine. Large-scale data analysis, predictive modeling, drug optimization, and personalized treatments are making healthcare more effective and tailored to individual needs.

ENHANCING PERSONALIZED MEDICINE: THE ROLE OF AI IN PHARMACOGENOMICS

Improved Drug Efficacy and Safety

AI has brought about a significant change in the pharmacogenomics field by enabling the development of enhanced drugs that directly relate to a patient's genetic makeup. Big data involving genomics is utilized in contexts such as patient care, where specific algorithms in AI predict how patients will respond to certain medications in terms of efficacy and side effects (Taherdoost & Ghofrani, 2024). AI, through the integration of machine learning and genomic and clinical data, can analyze various genes and derive insights that inform drug metabolism, thereby prescribing medications that are both effective and safe for patients (Marques et al., 2024).

Another benefit of using pharmacogenomics in conjunction with AI technology is the reduction of adverse drug reactions (ADRs). ADRs are a severe problem in clinical pharmacology that results in hospitalization and escalating costs of health care. Researchers have noted that AI models can predict medication-gene interactions before prescribing a drug, thereby minimizing adverse effects (Primorac et al., 2020). This capability helps improve the protection and outcomes for many patients, aligning with the objective of individualized treatment based on specific genetic factors rather than a generalized approach (Silva et al., 2024).

Accelerated Drug Discovery and Development

Through the help of innovation and development, AI has also reduced the time required to conduct clinical trials, which are often considered lengthy and expensive. Artificial intelligence algorithms are capable of scanning biochemical and genetic data and shortening the time spent on preclinical research of potential drugs (Boniolo et al., 2021). The drug-binding models enable scientists to predict drug interactions on a molecular level, assessing their efficiency and toxicity in humans through a more comprehensive comparison with extensive trials on human subjects (Chen et al., 2025).

A novel application of AI in pharmacogenomics is drug repurposing, where existing drugs are repurposed for new functionalities. Such predictive analysis enables researchers to combine an existing database of known drugs with new targets related to identified diseases at the genetic level, thereby accelerating the process of providing treatment options (Ahmad et al., 2023). It also brings efficiencies in terms of research and development, effectively lowering the risk associated with new drug development from discovery (Navarro, 2023).

AI Application	Impact
AI in Clinical Trials	Reduces the time and cost of lengthy clinical trials by efficiently analyzing biochemical and genetic data.

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

AI in Preclinical Research	AI scans genetic data to identify potential drugs more quickly, thereby reducing the duration of preclinical research.
AI in Drug Binding Models	Predicts drug interactions at the molecular level, assessing both efficiency and toxicity prior to human trials.
Drug Repurposing with AI	Identifies new uses for existing drugs by analyzing genetic-level disease data.
Predictive Analytics in Drug Discovery	Speeds up treatment availability and lowers risks associated with developing new drugs.

This table provides a structured view of how AI contributes to faster and more efficient drug development.

Enhanced Clinical Decision Support

CDS technologies utilize AI in clinical practice as a tool to support healthcare personnel by providing decision support and recommendations on medication choice, dosage selection, and potential drug interactions. These systems enable clinicians to make evidence-based decisions informed by patients' genetic data, thereby informing their treatment plans (Lin et al., 2020). AI aids designers in achieving superior results when prescribing medications for patients with complex diseases, such as cancer and psychiatric disorders, as pharmacogenomic differences are fundamental (Pardiñas et al., 2021).

Moreover, information technology, mainly through the use of artificial intelligence, has brought about changes in the management of precision medicine by integrating it with electronic health records. EHR also enables AI algorithms to extract genomic and clinical data for a precise treatment plan based on a patient's medical records and their genetic profile (Dhieb & Bastaki, 2025). It is advantageous because it increases the effectiveness of the delivery of healthcare through availing real-time data for physicians hence improving the healthcare outcomes and patient compliance (Weinshilboum & Wang, 2017).

CHALLENGES AND ETHICAL CONSIDERATIONS IN AI-DRIVEN PHARMACOGENOMICS

Data Privacy and Security Concerns

Among the most critical issues that need to be addressed in the context of AI for pharmacogenomics are the privacy and security of genotypic data. Because pharmacacogenomics utilizes an individual's genetic information to determine drug therapy, such information is considered private and sensitive, and thus it should be protected from those who would misuse it (Silva et al., 2024). Unlike typical PII, the leakage of data in this field poses more than a simple privacy invasion, as identity theft, insurance, and employment may be influenced by such leakage, leading to ethical issues (Abdelhalim et al., 2022).

First, it is worth noting that large databases are particularly vulnerable to hackers, as genetic data is considered highly valuable in scientific and business endeavors (Primorac et al., 2020). Although advanced approaches, such as encryption and blockchain, are available to safeguard genetic information, the risk of a breach is higher due to the interactions between data and AI (Marques et al., 2024). Additionally, uncertainties surrounding how patients' genomic data will be stored, who will share it, and for what purpose it will be used to train an AI model will raise informed consent issues (Taherdoost & Ghofrani, 2024).

This additional concern is related to the cross-border transfer of such information. AI-Pharmacogenomics research often involves working in different institutions or in different countries to share the data collected, but the different data protection policies may make it unethical to share the information (Weinshilboum & Wang, 2017). For

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

instance, the EU's General Data Protection Regulation (GDPR) has stringent rules on data privacy; therefore, other areas may not offer the same level of protection in AI-delivered healthcare (Boniolo et al., 2021).
Therefore, great expectations for AI-driven pharmacogenomics can be achieved if sound security measures are implemented, international data protection is upheld, and patient enrollment is practical and legal.

Regulatory and Ethical Issues in AI-Driven Pharmacogenomics

Therefore, the use of AI in pharmacogenomics for delivering precision medicine must observe certain regulatory milestones before it can be implemented in the clinical setting. Currently, there are no clear policies governing the application of pharmacogenomic interventions through artificial intelligence, resulting in variation in their use across different healthcare organizations and legal frameworks (Taherdoost & Ghofrani, 2024). The lack of a well-defined set of practices means that the use of AI linked to pharmacogenomics poses challenges in terms of approval and hinders efforts to build an interconnected world related to precision medicine (Silva et al., 2024).
One of the first ethically significant issues that should be addressed is the project of autonomy and informed consent in the context of pharmacogenomics, particularly when informed by artificial intelligence. Patients may be uninformed about how AI models operate and contribute to the decisions made regarding their care, which raises questions about medical transparency (Marques et al., 2024). As previously mentioned, unlike traditional pharmacogenomic approaches, machine-learning models tend to be 'black boxes'; therefore, clinicians and patients cannot easily understand how a specific treatment choice was derived (Chen et al., 2025). This absence of explanation can breed apprehension among medical personnel and the public, especially among patients or caregivers who may not trust an automated system to make decisions on their behalf (Boniolo et al., 2021).
In addition, AI-based pharmacogenomics is accompanied by specific policies that emphasize fairness, accountability, and equity, among other values. This may mean that current AI algorithms, which are trained on these datasets, could further exacerbate disparities across populations depending on the outputs provided to doctors (Pardiñas et al., 2021). Some regulatory agencies need to establish strict policies that verify the training sets used or the models to be tested before they are adopted for clinical practice (Dhieb & Bastaki, 2025).
Lastly, there is an acute awareness of the need to explain liability issues in pharmacogenomics with the use of AI. Suppose a particular recommendation given by an AI has negative impacts. In that case, it remains unclear whether the blame should be attributed to the healthcare provider, the AI programmer, or the organization that has adopted the technology (Primorac et al., 2020). Policies on accountability would be an essential guide towards ensuring that the pharmacogenomics working under artificial intelligence meets the required ethical standards (Weinshilboum & Wang, 2017). These questions underscore that the use of AI in pharmacogenomics is accompanied by potential legal concerns, highlighting the need for stronger regulation in this area, more straightforward guidelines, and equitable distribution of AI-based therapies. The proposition of addressing these issues underscores the need for a multidisciplinary approach, with policymakers, researchers, and healthcare practitioners collaborating to develop AI technologies for precision medicine that are safe, reliable, and ethical.

Validation and Trust in AI Models in Pharmacogenomics

The accuracy and acceptance of AI algorithms in pharmacogenomics primarily depend on the mental health of the models. Before embracing artificial intelligence-based predictions in personalized medicine, these predictions must undergo several tests in the clinic. Without proper validation, there may be bias and incorrect recommendations given to patients, leading to the provision of inadequate or even detrimental treatment that can be of no help to the patient. This paper acknowledges that the accuracy of an AI model is highly dependent on the quality of the datasets that are used in the modeling process. However, many models are trained on substantially nondiverse datasets that is why it contains significant prejudice concerning specific demographics (Weinshilboum & Wang, 2017).
When considering an algorithm trained on a genetic dataset from Western or European populations, it cannot capture variation in individuals of color. This can lead to inaccurate recommendations of drugs and perpetuating instead of minimizing many disparities in health care (Pardiñas et al., 2021). This is because the minority population may be subjected to more adverse drug reactions or inefficiency of the treatment. After all, the model's dataset may not include minority genetic markers. To overcome this challenge, it is necessary to obtain a large sample size that encompasses diverse populations across various ethnic and geographical regions (Dhieb & Bastaki, 2025).
Advanced AI models require further intricate certification and validation through live simulations and experiments within the clinical setting. AI-generated predictions should not be accepted solely based on their performance in an ideal environment but rather should be compared to the actual outcomes of patients in clinical scenarios (Chen

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

et al., 2025). This is useful in identifying existing weaknesses, improving the algorithm, and establishing credibility between healthcare workers and patients. It is equally important that these decision-making processes are transparent, especially regarding their use of artificial intelligence. This is a concern because if clinicians are unable to comprehend how an AI system arrives at its conclusions, there is little chance that they will use the system to make significant healthcare decisions.

Thus, people's trust in AI models also has its strengths and weaknesses, for it is also crucial to eliminate bias at all stages, including data acquisition and model development. They can appear not only because of incomplete information but also due to the preconceptions embedded in the machine learning algorithms. If these biases are not addressed,, they exacerbate already existing issues with the inferiority of precision medicine for specific individuals. This implies that researchers must consider bias mitigation measures for prognosis in facilities where adversarial formation and reality-aware algorithms are developed. For this reason, regulatory agencies are required to establish specific criteria that must be met by AI-driven pharmacogenomic tools before they are deployed for use in real-world practice (Marques et al., 2024).

However, model validation and data inclusiveness, along with a need for a transparent approach, will help AI realize its full potential in pharmacogenomics, delivering variant-agnostic personalized medicine for everyone.



The Distribution of AI Applications in Pharmacogenomics.

DISCUSSION

Pharmacogenomics has significantly benefited from the advancement of artificial intelligence, which has bridged the gap in drug prescriptions to enhance the effectiveness of treatment. Moreover, solutions provided by AI in the drug response predictions help to minimize the ADR and, in the process of drug discovery, significantly speed up the development. However, despite such promise, pharmacogenomics that relies on artificial intelligence has some challenges that need to be addressed for it to gain broader acceptance in clinical practice.

The first concern is the proper handling, storage, and protection of data collected for the research. The systems applied in pharmaceutical genomics involve massive amounts of genomic and clinical data, which means that the data can be hacked, leading to significant ethical issues. It must be noted that the disclosure of genetic data entails strict measures to preserve privacy, as patients' information is highly sensitive (Dhieb & Bastaki, 2025). This means that in the absence of some form of encryption coupled with secure methods of sharing inherited genetic

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

data, there are scenarios whereby the genetic details could be misused, thereby raising ethical and legal issues. Such risks can only be prevented if standard approaches to AI governance and data protection are implemented to ensure confidence among patients and healthcare practitioners.

Another important issue is the ethical implications of decisions made with the aid of artificial intelligence. Although it is now possible to predict the response of a drug at a highly accurate rate, it should be understood that these systems are black box algorithms. Such structure lack of interpretability raises three aspects unique accountability issues in clinical practice, significantly when AI-based recommendation impacts on critical decision-making (Weinshilboum & Wang, 2017). The paper also calls for clinicians to understand how AI models make predictions, ensuring that proposed prescriptions align with the best practices and ethical standards of the medical profession. To help avoid this, there should be specific guidelines on how the use of AI will be explained, ensuring that pharmacogenomic decisions made through AI are understandable and clinically responsible.

Lastly, there is an issue of model validation and a lack of trust in their outputs. Recent results depend significantly on the training data, but many datasets are non-diverse; for this reason, certain groups of people are often left behind during the training process (Pardiñas et al., 2021). This bias can create differences in the quality of treatment that can also be felt in pharmacogenomic studies because some participants from the minorities will not be involved in the study. To this end, AI models require training on diverse and inclusive data that encompasses different genetic variations worldwide. Moreover, external validation is also a critical step to ensure that the findings from AI pharmacogenomic models are consistent with benchmarks achieved through large-scale, real-world studies (Chen et al., 2025).

Despite these challenges, the benefits of AI-driven pharmacogenomics outweigh its limitations. The current data also prove the ability of AI in increasing drug effectiveness, decreasing the ADR impact, and optimizing drug creation. Machine learning and other approaches to big data analysis improve the efficacy of clinical decisions about patients and deliver effective care with higher efficiency. For instance, in oncology, there has been the application of pharmacogenomic models based on artificial neural networks, which has helped in the right selection of targeted therapies for cancer patients, leading to enhanced survival rates (Primorac et al., 2020). Within psychiatry, the use of artificial intelligence in selecting antidepressants has eliminated the long process of trial with the consequent beneficial effects on the patients (Pardiñas, Owen, & Walters, 2021). These achievements demonstrate that AI can significantly enhance personalized medicine and alter the approach to patient treatment.

Thus, the inclusion of pharmacogenomics should be exercised in the future with the involvement of artificial intelligence experts in cooperation with geneticists, clinicians, and policymakers. Therefore, ethical, regulatory, and validation factors will be among the key aspects that need to be addressed to make A.I.O., as well as pharmacogenomics in general, a reliable tool in precision medicine. Specifically, by being open-source, bias-checked, institutionally backed, and solidly validated, AI alone should be given the chance to revolutionize drug response prediction and individualized treatments.

CONCLUSION

The regular use of AI in conjunction with pharmacogenomics is one of the most significant innovations in the field of medicine today since it provides highly accurate predictions of the patient's response to certain medications, as well as an indication of how best to improve the effectiveness of existing treatments or even the development of new drugs. AI enhances the process of analyzing large volumes of genomic information, thanks to the application of machine learning and deep learning; healthcare professionals are, therefore, able to identify appropriate medications for patients according to their respective genes. It has been established that the effect of this innovation includes improved efficacy, reduced adverse drug reactions, and accelerated drug discovery.

Nevertheless, the following challenges must be addressed for pharmacogenomics based on artificial intelligence to be easily integrated into clinical practice. Other issues include data privacy and security, as the management of genetic information involves access to sensitive data that could cause significant harm if leaked to the public domain. Issues such as the success of the clinical setup and the leadership of clinical decisions by the decision-making entity, the AI, are also ethical concerns that need to be addressed to enhance trust between the clinician and the patient. Additionally, problems of fairness, particularly the influence of potential sources of bias in the models, must be addressed through the proper testing of AI models on diverse, real-life patients.

Subsequent work should, therefore, engage AI scientists, genetic scientists, clinicians, and policymakers to improve on the application of AI in pharmacogenomics. In terms of current limitations, they can be overcome by implementing standard rules of artificial intelligence governance, expanding the number of datasets, and

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

enhancing the model's transparency. Today, it is possible to foresee that the role of pharmacogenomics in precision medicine will expand dramatically due to the progressive developments in artificial intelligence and bioinformatics.

REFERENCE

1. Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., et al. (2024). Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology, and Personalized Healthcare. *Pharmaceutics*, 16(3), 332. https://doi.org/10.3390/pharmaceutics16030332
2. Taherdoost, H., & Ghofrani, A. (2024). Artificial Intelligence and the Evolution of Personalized Medicine in Pharmacogenomics. *Intelligent Pharmacy*. https://doi.org/10.1016/j.intpha.2024.100011
3. Primorac, D., Bach-Rojecky, L., Vađunec, D., Juginović, A., Žunić, K., Matišić, V., et al. (2020). Pharmacogenomics at the Center of Precision Medicine: Challenges and Perspectives in an Era of Big Data. *Pharmacogenomics*, 21(2), 141–156. https://doi.org/10.2217/pgs-2019-0111
4. Jyothi, N. M. (2023). AI-Enabled Genomic Biomarkers: The Future of the Pharmaceutical Industry and Personalized Medicine. *Seybold Report Journal*, 18(08), 54–72.
5. Lin, E., Lin, C.-H., & Lane, H.-Y. (2020). Precision psychiatry applications with pharmacogenomics: artificial intelligence and machine learning approaches. *International Journal of Molecular Sciences*, 21(3), 969. https://doi.org/10.3390/ijms21030969
6. Abdelhalim, H., Berber, A., Lodi, M., Jain, R., Nair, A., et al. (2022). Artificial intelligence, healthcare, clinical genomics, and pharmacogenomics approaches in precision medicine. *Frontiers in Genetics*, 13, 929736. https://doi.org/10.3389/fgene.2022.929736
7. Ahmad, H. I., Hameed, H., Abbas, M., & Jabar, A. (2023). Integrating genomics and precision medicine. In M. Ozaslan & M. Safdar (Eds.), *Current Studies in Health and Life Sciences 2023* (pp. 284–300).
8. Chen, Y.-M., Hsiao, T.-H., Lin, C.-H., & Fann, Y. C. (2025). Unlocking Precision Medicine: Clinical Applications of Integrating Health Records, Genetics, and Immunology through Artificial Intelligence. *Journal of Biomedical Science*, 32, 16. https://doi.org/10.1186/s12929-024-01110-w
9. Kumar, A. (n.d.). AI-driven precision oncology: predictive biomarker discovery and personalized treatment optimization using genomic data.
10. Chowdhury, R., Kalita, R., & Sharma, H. K. (n.d.). Personalized Medicine and Pharmacogenomics: Pioneering the Future of Precision Healthcare.
11. Navarro, J. (2023). AI in Genomic Medicine: Enhancing Precision Medicine through Genetic Data Analysis. *Advances in Computer Science, Vol. 6, No. 1*.
12. Boniolo, F., Dorigatti, E., Ohnmacht, A. J., et al. (2021). Artificial intelligence in early drug discovery enabling precision medicine. *Expert Opinion on Drug Discovery*, 16(9), 949–959. https://doi.org/10.1080/17460441.2021.1918096
13. Silva, L., Pacheco, T., Araújo, E., Duarte, R. J., Ribeiro-Vaz, I., & Ferreira-da-Silva, R. (2024). Unveiling the Future: Precision Pharmacovigilance in the Era of Personalized Medicine. *International Journal of Clinical Pharmacy*, 46(1), 3349. https://doi.org/10.1007/s11096-024-01709-x
14. Pardiñas, A. F., Owen, M. J., & Walters, J. T. R. (2021). Pharmacogenomics: A Road Ahead for Precision Medicine in Psychiatry. *Neuron*, 109(14), 2104–2117. https://doi.org/10.1016/j.neuron.2021.05.030
15. Weinshilboum, R. M., & Wang, L. (2017). Pharmacogenomics: Precision Medicine and Drug Response. *Mayo Clinic Proceedings*, 92(11), 1711–1722. https://doi.org/10.1016/j.mayocp.2017.08.001
16. Lorkowski, J., Kolaszyńska, O., & Pokorski, M. (2021). Artificial Intelligence and Precision Medicine: A Perspective. In *Integrative Clinical Research* (pp. 1–11). Springer. https://doi.org/10.1007/5584_2021_652

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

17. Das, S., Mazumder, S., Alam, N., Vernekar, M., Dam, A., Bhowmick, A. K., et al. (2024). Precision Oncology in the Era of Genomics and Artificial Intelligence. *Journal of Current Oncology Trends*, 1(1), 22–30.
18. Dhieb, D., & Bastaki, K. (2025). Pharmaco-Multiomics: A New Frontier in Precision Psychiatry. *International Journal of Molecular Sciences*, 26(3), 1082. https://doi.org/10.3390/ijms26031082
19. Verga, J. U., Lloyd, A., Sarron, A., & Hardiman, G. (2024). Advances in genomic technology and the promise of precision medicine. In *Therapeutic Drug Monitoring: Newer Drugs and Biomarkers* (2nd ed., pp. 355–371). Elsevier. https://doi.org/10.1016/B978-0-443-18649-3.00007-0
20. Srivastav, A. K., Das, P., & Singha, T. (2024). AI and Biotech in Pharmaceutical Research: Synergies in Drug Discovery.